U.S. markets closed
  • S&P Futures

    4,272.75
    -8.25 (-0.19%)
     
  • Dow Futures

    33,657.00
    -61.00 (-0.18%)
     
  • Nasdaq Futures

    13,550.50
    -27.25 (-0.20%)
     
  • Russell 2000 Futures

    2,013.20
    -3.70 (-0.18%)
     
  • Crude Oil

    91.75
    -0.34 (-0.37%)
     
  • Gold

    1,816.50
    +1.00 (+0.06%)
     
  • Silver

    20.76
    +0.07 (+0.32%)
     
  • EUR/USD

    1.0263
    -0.0063 (-0.61%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • Vix

    19.53
    -0.67 (-3.32%)
     
  • GBP/USD

    1.2132
    -0.0070 (-0.58%)
     
  • USD/JPY

    133.5050
    +0.5060 (+0.38%)
     
  • BTC-USD

    24,342.85
    -104.53 (-0.43%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.68 (+2.62%)
     

Phase III Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implant

·2 min read
Alimera Sciences, Inc.
Alimera Sciences, Inc.

ATLANTA, June 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that its partner, Ocumension Therapeutics (“Ocumension”) received approval from the National Medical Products Administration for its IND application to begin the Phase III clinical study for fluocinolone acetonide intravitreal implant in support of a filing for marketing approval to treat diabetic macular edema in mainland China.

“We are very excited by the progress that Ocumension is making toward generating the data needed to seek approval in China for our intravitreal implant,” said Rick Eiswirth, President and CEO of Alimera. “We look forward to the start of the trial and to the subsequent data.”

The IND application was for a randomized, multicenter Phase III clinical study of 0.19 mg Fluocinolone Acetonide Intravitreal Implant in the treatment of diabetic macular edema. The intent of the trial is to support a future NDA filing to gain marketing approval in the country with an equivalent indication to Alimera’s U.S. indication (for the treatment of diabetic macular edema previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure).

About Alimera
Alimera is a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com

About Ocumension Therapeutics
Ocumension is an ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. The Group has a portfolio of 23 drug assets, covering all major front- and back-of-the-eye diseases, among which seven key drug candidates are in phase III clinical trial stage.

For press inquiries:
Jules Abraham
for Alimera Sciences
917-885-7378
julesa@coreir.com

For investor inquiries:
Scott Gordon
for Alimera
scottg@coreir.com